1. Home
  2. TURN vs INTS Comparison

TURN vs INTS Comparison

Compare TURN & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TURN
  • INTS
  • Stock Information
  • Founded
  • TURN 1981
  • INTS 2012
  • Country
  • TURN United States
  • INTS United States
  • Employees
  • TURN N/A
  • INTS N/A
  • Industry
  • TURN Finance/Investors Services
  • INTS Biotechnology: Pharmaceutical Preparations
  • Sector
  • TURN Finance
  • INTS Health Care
  • Exchange
  • TURN Nasdaq
  • INTS Nasdaq
  • Market Cap
  • TURN 39.6M
  • INTS 33.4M
  • IPO Year
  • TURN N/A
  • INTS 2023
  • Fundamental
  • Price
  • TURN $4.12
  • INTS $2.11
  • Analyst Decision
  • TURN
  • INTS Strong Buy
  • Analyst Count
  • TURN 0
  • INTS 3
  • Target Price
  • TURN N/A
  • INTS $8.50
  • AVG Volume (30 Days)
  • TURN 48.0K
  • INTS 33.1K
  • Earning Date
  • TURN 02-25-2025
  • INTS 03-13-2025
  • Dividend Yield
  • TURN N/A
  • INTS N/A
  • EPS Growth
  • TURN N/A
  • INTS N/A
  • EPS
  • TURN N/A
  • INTS N/A
  • Revenue
  • TURN $129,297.00
  • INTS N/A
  • Revenue This Year
  • TURN N/A
  • INTS N/A
  • Revenue Next Year
  • TURN N/A
  • INTS N/A
  • P/E Ratio
  • TURN N/A
  • INTS N/A
  • Revenue Growth
  • TURN 6.32
  • INTS N/A
  • 52 Week Low
  • TURN $3.12
  • INTS $1.50
  • 52 Week High
  • TURN $4.47
  • INTS $5.94
  • Technical
  • Relative Strength Index (RSI)
  • TURN 66.26
  • INTS 41.98
  • Support Level
  • TURN $3.85
  • INTS $1.84
  • Resistance Level
  • TURN $4.05
  • INTS $2.53
  • Average True Range (ATR)
  • TURN 0.13
  • INTS 0.32
  • MACD
  • TURN 0.00
  • INTS -0.02
  • Stochastic Oscillator
  • TURN 95.71
  • INTS 37.50

About TURN 180 Degree Capital Corp.

180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

Share on Social Networks: